



DEPARTMENT OF HEALTH AND HUMAN SERVICES

HFI-35

m34651

Food and Drug Administration
Cincinnati District Office
6751 Steger Drive
Cincinnati, OH 45237-3097
Telephone: (513) 679-2700
FAX: (513) 679-2772

WARNING LETTER

Cin WL-1667-0

February 7, 2000

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Kevin Hackett, M.D.
Owner
Professionals for Womens Health
3045 Olentangy River Road
Columbus, OH 43202

Facility I.D.#: 156729

Dear Dr. Hackett:

A representative from the State of Ohio radiation control program under contract to the Food and Drug Administration inspected your facility on February 1, 2000. This inspection revealed that your facility failed to comply with the Quality Standards for Mammography (Standards) as specified in Title 21, Code of Federal Regulations (CFR), Part 900.12, as follows:

Your standard operating procedures are inadequate for your facility in communicating to the patients the results of their mammograms. Your standard operating procedures fail to indicate that the suspicious or highly suggestive for malignancy mammography results will be communicated in a lay summary report to each patient. This shall be performed in addition to your practice of verbally informing the patient of the serious or highly suggestive for malignancy mammography results. **21 CFR 900.12(e)(1)**

The specific deficiency noted above appeared under the Level 1 heading on your MQSA Facility Inspection Report, which was issued at the close of the inspection. This deficiency may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility.

It is your responsibility to ensure adherence to each requirement of the Mammography Quality Standards Act of 1992 (MQSA) and FDA's regulations. You are responsible for investigating and determining the causes of the deficiencies that the inspection identifies and promptly initiate permanent corrective actions.

If you fail to promptly correct this deficiency, FDA may, without further notice, initiate regulatory action. Under MQSA, FDA may:

- Impose civil money penalties on a facility of up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.

- Suspend or revoke a facility's FDA certificate for failure to comply with the Standards.
- Seek an injunction in federal court to prohibit any mammography activity that constitutes a serious risk to human health.

Within 15 working days after receiving this letter, you should notify FDA in writing of:

- The specific steps you have taken to correct all of the violation noted in this letter;
- Each step your facility is taking to prevent the recurrence of similar violation;
- Sample records that demonstrate proper record keeping procedures related to quality control.

If your facility is unable to complete the corrective action within 15 working days, you should state the reason for the delay and the time within which the corrections will be completed.

Please send the original copy of your response to:


R. Terry Bolen
MQSA Compliance Officer
Food and Drug Administration
6751 Steger Dr.
Cincinnati, OH 45237-3097

Also, please send a copy to the State radiation control office:

Ms. Allison Sincek
Ohio Department of Health
246 N. High St., 5th Floor
Columbus, OH 43215

If you have any questions regarding this letter or how to ensure you are meeting MQSA standards, please call R. Terry Bolen at (513) 679-2700, extension 138.

Sincerely yours,



Henry L. Fielden
District Director
Cincinnati District Office

c.
OH/ASincek

Director, Breast Imaging Accreditation Program
American College of Radiology
1891 Preston White Dr.
Reston, VA 20191